

November 11, 2025

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Ref: (i) Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
(ii) SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sub: Investors Presentation- Quarter II and half year ended on September 30, 2025 – Orchid Pharma Limited ("the Company")

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30, Sub- Para 15 of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and in continuation to our earlier intimation dated November 05, 2025 regarding the Analysts/Investors Earning Call scheduled to be held on November 11, 2025 at 04:30 P.M. (IST), please find enclosed the Investors Presentation, inter-alia, including the financial performance of the Company for the Quarter-II and half year ended on September 30, 2025.

The Investor Presentation is also made available on the website of the Company.

You are requested to take the above intimation on record.

Thanking You,
For **Orchid Pharma Limited**

Kapil Dayya
Company Secretary & Compliance Officer
Mem. No.- F10698

Encl. as above

Orchid Pharma Limited

Financials Q2 FY-26


- All results in standalone basis.
- These are approx. or exact nos. pls refer financials for details.

Financial Performance




(Amt. in Cr.)	Q2-26	Q2-25	Change %	H1-26	H1-25	% Change
Sales	194	223	-13%	366	467	-22%
Other Income	15	8	+88%	31	16	+94%
COGS	132	131	+1%	231	281	-18%
Employee Exp	24	21	+14%	46	42	+10%
Other Exp	38	41	-7%	76	81	-6%
EBITDA*	15	38	-61%	44	79	-44%
% to Sales	8%	17%		12%	17%	
Interest	4	3	+33%	7	7	0%
Depreciation	9	9	0%	17	17	0%
PBT	2	26	-92%	20	55	-64%
PAT	2	26	-92%	20	55	-64%


Turnover (Amt. in Cr.)




EBITDA, PBT & PAT as % to Sales Q2-26



P&L Analysis – Gross Margin % to Sales Q2-26



P&L Analysis – Exp. % to Sales Q2-26



Thank You